2022
DOI: 10.1039/d2md00004k
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and anticancer activity of two highly water-soluble and ionic Pt(iv) complexes as prodrugs for Pt(ii) anticancer drugs

Abstract: Two new Pt(IV) complexes featuring mesylate as outer sphere anions, cis,trans,cis-[PtCl2(OH2)2(NH3)2](CH3SO3)2 (SPt-1) and cis,trans,cis-[PtCl2(OH2)2 (1R,2R-DACH)](CH3SO3)2 (SPt-2), were synthesized, and characterized by elemental analysis, 1H- and 13C-NMR,IR, and ESI-MS. Both complexes...

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 25 publications
(47 reference statements)
0
1
0
Order By: Relevance
“…Every year, about 13.2 million people worldwide die of cancer, and an estimated 21.4 million additional cases will occur by 2030, which is also expected to overtake those of communicable diseases in the next decade [ 2 , 3 ]. Despite ongoing efforts to increase the availability of platinum-based drugs such as cisplatin, carboplatin, lobaplatin, oxaliplatin, heptaplatin, nedaplatin, and miriplatinhydrate for chemotherapeutic treatment in recent decades [ 4 , 5 ], cancer mortality rates have not yet decreased significantly owing to these medications' limited efficacy, nonselectivity, resistance, and high-risk profiles. Numerous intrinsic limitations arise because of covalent interactions with DNA.…”
Section: Introductionmentioning
confidence: 99%
“…Every year, about 13.2 million people worldwide die of cancer, and an estimated 21.4 million additional cases will occur by 2030, which is also expected to overtake those of communicable diseases in the next decade [ 2 , 3 ]. Despite ongoing efforts to increase the availability of platinum-based drugs such as cisplatin, carboplatin, lobaplatin, oxaliplatin, heptaplatin, nedaplatin, and miriplatinhydrate for chemotherapeutic treatment in recent decades [ 4 , 5 ], cancer mortality rates have not yet decreased significantly owing to these medications' limited efficacy, nonselectivity, resistance, and high-risk profiles. Numerous intrinsic limitations arise because of covalent interactions with DNA.…”
Section: Introductionmentioning
confidence: 99%